Riders · Department of State Health Services · Article II: Health and Human Services
HIV Vendor Drug Rebate Funding Loss Replacement
Rider 37 in the House passed, page II-32
This rider is not in the Conference or any later version.
Through the session
- 2024-25 Act Not in this version
- Introduced (Senate) Not in this version
- Introduced (House) Not in this version
- Senate substitute Not in this version
- House substitute New rider 37
- House passed Unchanged rider 37
- Conference Dropped
- 2026-27 Act Not in this version
Pick any two steps to compare their wording.
What changed in the text
House substitute → House passed: the same text in both versions.
Removed words are struck through; added words are underlined. Sources: House substitute · House passed.
Every version: numbers, statuses and source pages
| Version | Rider | Against the version before | Against the current budget | Source |
|---|---|---|---|---|
| 2024-25 ActGeneral Appropriations Act, 2024-25 Biennium | Not in this version | |||
| Introduced (Senate)Senate Bill 1 as introduced (LBB recommended, Senate) | Not in this version | |||
| Introduced (House)House Bill 1 as introduced (LBB recommended, House) | Not in this version | |||
| Senate substituteCommittee Substitute for Senate Bill 1 | Not in this version | |||
| House substituteHouse Committee Substitute for Senate Bill 1 | 37 | New | New | Page II-32 |
| House passedSenate Bill 1 as passed the second house | 37 | Unchanged | New | Page II-32 |
| ConferenceConference Committee Report for Senate Bill 1 | Not in this version | |||
| 2026-27 ActGeneral Appropriations Act, 2026-27 Biennium | Not in this version | |||
Full text of each wording
House substitute, House passed
Source, page II-32HIV Vendor Drug Rebate Funding Loss Replacement. Included in the amounts appropriated above in Strategy A.2.2, HIV/STD Prevention, is $2,300,000 from the General Revenue Fund in fiscal year 2026 and $2,300,000 from the General Revenue Fund in fiscal year 2027 to replace funding from the loss of HIV Vendor Drug Rebates and to maintain funding for the HIV Medication program at the 2024-25 biennium level. Any unexpended and unobligated balances of these funds remaining at the end of the first fiscal year of the biennium are appropriated for the same purposes in the second fiscal year of the biennium.